Sentinel lymph node (SLN) biopsy for early cervical cancer achieved non-inferiority versus pelvic lymphadenectomy, according to results of a large randomized study from China. Patients assigned to SLN ...
Silence Therapeutics PLC Sponsored ADR (SLN) shares rallied 19% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being ...
Zacks Investment Research on MSN
SLN stock skyrockets 107% in six months: Here's what you need to know
Shares of Silence Therapeutics SLN have surged 107% over the past six months, driven by investor optimism around the ...
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...
Following discussions over the last weeks, the French State and Eramet have reached an agreement regarding the treatment of SLN's existing debt. This agreement will neutralize SLN's debt impact on the ...
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 5.7% in the last trading session to close at $22.36. The move was backed by solid volume with far more shares changing hands than in a normal ...
Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results